Main article: CDC pioneers family-based "preventive care" in Uganda as framework for rollout

By Theo Smart

"In a 2002 survey in Uganda, only 5% of health facilities could perform an HIV test, less than 1% were able to provide PMTCT services and only 10% could diagnose and treat tuberculosis - the leading killer of people with HIV in Africa," said Dr. Jonathan Mermin of the US Centers for Disease Control (CDC) in Uganda.

He and colleagues have been developing a framework for providing family-based clinical care for people with AIDS in Africa. Dr. Mermin described their experiences, including the addition of ART to the basic care programme, at a symposium last Tuesday at the 12^th Conference on Retroviruses and Opportunistic Infections in Boston.

Developing a basic package of preventive care

In the last few years, there has been a substantial increase in funding for HIV programmes, but how can antiretroviral treatment be delivered in a setting where few people have access to even the most basic health care?

"To begin to cope with providing HIV care in this context" said Dr. Mermin "we felt that it would be important to prevent illness as well as treat it. particularly in rural areas where the majority of people live several kilometres from a health centre and heath centres have only limited diagnostic and treatment capacity."

Rather than make people travel to care, his team explored what types of basic care could be delivered to people directly in their own homes, by providing people with as many of the tools for prevention of illness as possible.

"Our goal was to develop a standard package of evidence-based preventions that will reduce morbidity and mortality among persons with HIV and lower the chance or HIV transmission," said Dr. Mermin.

Since people with HIV live within a family and community context in rural Africa, the CDC approached interventions through the lens of treating the whole family. Focusing on the family increases the chances of success because it improves support for adherence and disclosure of HIV status - including negotiations about safer-sex.

Voluntary counselling and testing for family members

The first component of the programme is voluntary HIV counselling and testing (VCT), which is the entry point for care, support and prevention. The CDC felt that a logical expansion of traditional VCT would be to offer it to family members for two reasons.

First, people with HIV often assume their partner has HIV, and therefore neglect to practice safe sex. However, many relationships are actually sero-discordant - meaning one sexual partner has HIV and the other doesn't. Knowing both partners HIV status could reduce transmission.

Also, when one person is HIV-infected, a substantial proportion of family usually have undiagnosed HIV.

But most care and treatment programme do not currently provide VCT to family members. PMTCT programmes are at the forefront but they have had very limited success in getting partners to come to the clinic for testing.

To see whether taking VCT to families could work, the CDC conducted two studies in rural Uganda. "95% of 6,000 household members of persons with HIV accepted VCT - 98% in their home," said Dr. Mermin. The studies found that 35% of married HIV-infected subjects were in sero-discordant relationships and that 10% of children below 5 years of age were HIV-positive. Most of these infections were unknown to the parents.

Cotrimoxazole prophylaxis

The next component in the CDC's programme is cotrimoxazole prophylaxis, which, prevents infections and prolongs life in children and adults in Africa. A study in Uganda recently showed a 46% reduction in mortality and a 30-70% decrease in malaria, diarrhea, and hospitalisation.

Taking cotrimoxazole was associated with a reduced rate of decline in CD4 cell count and slowed the increase in viral load (as compared to untreated patients). Only 2% of people had adverse effects over one and a half years of follow-up.

Rates of clinical malaria in persons over five years of age fell dramatically over the course of the cotrimoxazole study -- in both HIV positive and HIV-negative members of the household. At the start of the study rates of malaria were twice as high in people with HIV - but the rate fell by over 75% after going on prophylaxis.

Rates of malaria fell 35% in people without HIV in the household when HIV-positive household members took cotrimoxazole. Finally, having an adult take cotrimoxazole was associated with a 63% reduction in death among HIV-negative children < 10 years old.

Diarrhoea and safe water vessels

In Africa, people with HIV have six times the usual rate of diarrhoea because of the lack of safe drinking water. To address this problem, the CDC and WHO have developed a safe water vessel (SWV) which involves chlorination and storage of water in home.

A randomised controlled trial of SWV use among 509 persons with HIV showed 25% fewer diarrhoea episodes, 33% fewer days with diarrhoea and less dysentery. They also benefited HIV-negative family members.

At a cost of only $4 per year per family, the CDC was quick to incorporate SWVs into the preventive package.

Bed nets

The CDC has recently introduced insecticide-treated bed nets to prevent malaria into the package, at a cost of $5 per net. Nets reduce malaria by 50% among children. Although never specifically evaluated among persons with HIV- who are at high risk of malaria, they are theoretically useful.

Other possible interventions being considered for the package

• Isoniazid (INH) prophylaxis

In people with HIV and a positive tuberculin skin test, INH prophylaxis for six to 12 months has been associated with a 60% decrease in active TB and a 20% reduction in mortality. However, active TB must first be screened out to prevent INH resistance.

• Multivitamins

Among pregnant women in Tanzania, multivitamins reduced progression to AIDS or death, reduced mother-to-child transmission of HIV, increased birth weight, and had a beneficial effects on CD4 count and viral load. Among children with HIV in Tanzania, vitamin A was associated with 63% reduction in mortality.

Other interventions

• Fluconazole prophylaxis may reduce incidence of cryptococcal disease, which is a significant cause of death in some settings. A study of fluconazole in Uganda is ongoing.
• Acyclovir prophylaxis - associated with reduction in mortality and lower risk of herpes and shingles outside of Africa.
• Food supplementation, which has never been clinically evaluated in Africa where many people are malnourished.

Adding antiretrovirals

Currently, the CDC is exploring whether their home-based AIDS care program (HBAC) can be expanded to deliver TB treatment and antiretroviral therapy (ART).

The programme identifies people with HIV, and enrols their whole family who are provided with VCT at home and sexual behaviour and drug adherence counselling. Treatment is provided to all adults and children in household with weekly home visits by lay workers. There are no scheduled clinic visits after enrolment.

The CDC is evaluating the programme with a 3-arm randomised controlled trial enrolling 1,000 people with AIDS and their family members. Arm A receives home visits, CD4 cell counts and viral loads; Arm B: home visits and CD4 cell counts and Arm C just receives home visits. The objectives of the study are to determine the need for routine viral load and CD4 cell counts and assess its cost-effectiveness.

Dr. Mermin shared some of the early HBAC experience. So far 2,127 persons with HIV have been screened. 1064 (50%) are eligible for ART by CD4 count <250 or clinical criteria. At screening, 8% had active TB. 49 children currently on ART

After one year, there have only been 71 deaths (7%); 61% of these occurred during first 12 weeks of therapy.

Adherence by pill count has been excellent (>99%). There has also been a 50% reduction in unprotected sex after six months with a 82% reduction in HIV transmission risk when reductions in viral load included in model.

In conclusion, Dr. Mermin said: "implementation of effective preventive care could save resources, and prolong lives of millions of people in Africa. [and, that] addition of ART and TB care to [the] package is possible."

Reference

Mermin J. Family-based Approach to Preventive Care and Antiretroviral Therapy in Africa.12th Conference on Retroviruses and Opportunistic Infections, Boston, abstract 2A, 2005.

News headlines

Is less than 95% adherence to NNRTIs good enough to lead to viral suppression?

http://www.aidsmap.com/en/news/4007926C-60CE-4A3D-9CB5-69753377ED26.asp?hp=1

Adherence to nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens does not need to be perfect to push a viral load below 400 copies/mL, according to results from a study of indigent San Franciscans presented at the 12th Conference on Retroviruses and Opportunistic Infections in Boston, Massachusetts. But shaky adherence to a single (unboosted) protease inhibitor (PI) regimen greatly lowered the chance of viral suppression in this group.

Pre-exposure prophylaxis may only offer limited benefit

http://www.aidsmap.com/en/news/F4EFF025-193B-4459-B3FC-AA5BD7096C71.asp?hp=1

A trial of tenofovir as pre-exposure prophylaxis against rectal exposure to HIV in rhesus monkeys has produced disappointing results, the 12th Retrovirus Conference was told on its final day in Boston.

Vanguard treatment programmes pave the way to scale up

http://www.aidsmap.com/en/news/F0362CA9-E3EE-463D-BF3B-0EA1EB4F6FFF.asp?hp=1

"Over the past couple years, there has been a confluence of events and most importantly, the determination to meet the ethical, social and medical imperative to actually provide access to care and treatment to the millions of people living with HIV."

Little difference in child transmission rates between formula feed and breast-plus-AZT

http://www.aidsmap.com/en/news/86A77A75-6B10-4542-9775-247C880EE382.asp?hp=1

Two studies presented on Thursday at the Twelfth Annual Retrovirus Conference in Boston have shown that the use of prophylaxis in babies breast-fed by HIV-positive mothers can reduce HIV transmission to comparable rates to formula-fed babies. However, this approach can increase the risk of the child developing resistance to the drugs used, at least temporarily.

Pregnant women with CD4 cell counts over 250 not at greater risk of nevirapine-related toxicity in Kenyan study

http://www.aidsmap.com/en/news/B89949C7-C2FC-4207-87B7-7E621A5EF406.asp?hp=1

A Kenyan study of nevirapine (Viramune) in pregnant women, most of whom had relatively high CD4 cell counts, has observed that the incidence of liver toxicity and serious allergic reactions is similar to that seen in other nevirapine trials. The study, reported this week at the Twelfth Annual Retrovirus Conference in Boston observed slightly more nevirapine toxicity in women with lower CD4 cell counts.

Three trials bring African mother to child transmission down to four per cent; WHO vows to reconsider guidelines

http://www.aidsmap.com/en/news/819CD092-3764-4C00-9C68-66E9BA35AA9D.asp?hp=1

Three trials of various regimens of nevirapine plus NRTIs to prevent mother-to-baby transmission of HIV have brought the infection rate among newborn babies down to between below five per cent, the 12th Retrovirus Conference in Boston heard on Thursday.

Six- and nine-month courses of TB treatment equivalent in Indian HIV-positive patients

http://www.aidsmap.com/en/news/F093DBCD-70F6-499B-8631-D718F74E3952.asp?hp=1

A six-month course of tuberculosis (TB) treatment resulted in a similar cure rate to a nine-month course in HIV-positive patients in India, according to a study presented on Friday at the Twelfth Annual Retrovirus Conference in Boston. This suggests that this approach may help to reduce the cost of TB treatment in resource-limited settings with a high prevalence of HIV.

Single-dose nevirapine reduces HIV transmission in second delivery

http://www.aidsmap.com/en/news/0507DD7B-0FD6-4A3F-BB67-5E71638EE5EC.asp?hp=1

HIV-positive mothers who have previously used single-dose nevirapine to prevent passing on HIV to their baby during delivery can use the same procedure to prevent transmission in a second delivery, according to the results of a pilot study presented on Thursday at the Twelfth Annual Retrovirus Conference in Boston.

Pregnancy doubles the risk of HIV infection

http://www.aidsmap.com/en/news/2FFFA96F-EF36-42C2-8BBF-8EE2291C75DB.asp?hp=1

Women are more vulnerable to HIV infection when they are pregnant, with an infection rate more than double that among other women, a study from Uganda has found.

Long-term CD4 increase on HAART averages 250-350 cells, plateaus after 3-4 years

http://www.aidsmap.com/en/news/25878359-FEA1-4747-976A-64EF54A65D30.asp?hp=1

A series of four poster presentations at the 12th Retrovirus Conference looked at the immune recovery of patients staying on HAART for periods of between three and seven years and found that the average CD4 count increase achievable on HAART appears to be in the region of 350. They found median CD4 increases varying from 230 over 3.6 years in a Spanish study to 337 over 4.75 years in a French one.

The 'New York case': details revealed at Boston conference

http://www.aidsmap.com/en/news/49C38CB4-6D78-4B43-8503-4E9FA34F0110.asp?hp=1

In response to recent media reports about a New York man apparently infected with an 'aggressive' strain of HIV that is 'impossible to treat', attendees at the Twelfth Annual Retrovirus Conference heard what is known - and what is not known - about the case, at an additional session on Thursday evening.

Highly sensitive method uncovers high levels of resistance in mothers given single-dose nevirapine

http://www.aidsmap.com/en/news/379A4719-2FBD-49F8-8353-E3FDFF72F567.asp?hp=1

A sophisticated laboratory test has demonstrated that single-dose nevirapine given to mothers can lead to a higher incidence of resistance than detectable by standard assays, according to three similar studies presented on Thursday at the Twelfth Annual Retrovirus Conference in Boston.

D for death, not A B or C, is main cause of decline in Ugandan HIV prevalence

http://www.aidsmap.com/en/news/269D81D6-FDC2-4745-B6BC-76CA718B2217.asp?hp=1

Mortality, not behavioural change, is the main cause of the decline in HIV prevalence seen in Uganda during the last decade, a study from the Rakai district suggests.

Fish oils can reverse high blood lipids caused by antiretrovirals

http://www.aidsmap.com/en/news/EC8DDC7F-A007-4A10-ACDC-3C70185FA5E8.asp?hp=1

Increased levels of blood lipids caused by the administration of antiretroviral drugs can be decreased by fish oil capsules, according to the results of a randomised controlled trial presented on Wednesday at the Twelfth Annual Retrovirus Conference in Boston.

NNRTI-based HAART effective in Thai children

http://www.aidsmap.com/en/news/0485BC33-D88E-4E86-81B9-265F0DBDB607.asp?hp=1

Highly active antiretroviral therapy (HAART) based on generic non-nucleoside reverse transcriptase inhibitors (NNRTIs) is feasible and effective in treated children with advanced HIV disease in resource-limited settings, according to a presentation on Wednesday at the Twelfth Annual Retrovirus Conference in Boston.

3 x 5: South Africa, India, Nigeria `have to start moving` says WHO

http://www.aidsmap.com/en/news/77C1AB07-282C-4658-94BB-BD6F3C8BACE8.asp?hp=1

There is a strong likelihood that the World Health Organization's 3 x 5 target to get three million people onto antiretroviral treatment by the end of 2005 could fail unless governments in South Africa, India and Nigeria show greater commitment to reaching treatment targets, according to Dr Jim Kim of the World Health Organization. He was speaking on the opening day of the Twelfth Annual Retroviruses conference, held this year in Boston, USA.

South Africa completes negotiations for large-scale antiretroviral procurement

http://www.aidsmap.com/en/news/5C4983F9-7A77-491C-8FB1-D56D64590D02.asp?hp=1

On February 18, South African Health Minister Manto Tshabalala-Msimang announced that her department has completed negotiations with drug companies to supply antiretroviral drugs to state hospitals. The tenders are to be awarded "shortly."

South Africans march to accelerate rollout of antiretroviral treatment

http://www.aidsmap.com/en/news/60EC6DB0-BA24-4D12-952E-21D0240D11CF.asp?hp=1

About 5,000 protestors marched on the South African Parliament Building in Cape Town on Wednesday, February 16th, demanding that the government speed up the rollout of antiretroviral treatment (ART) to its citizens with HIV. The marchers, rallied by the Treatment Action Campaign (TAC), demanded that the government put 200,000 patients (at least ten percent of which should be children) on ART by February next year.